Current Report Filing (8-k)
February 08 2021 - 4:11PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 2, 2021
One
World Pharma, Inc.
(Exact
name of registrant as specified in charter)
Nevada
|
|
333-200529
|
|
61-1744826
|
(State
or other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
3471
West Oquendo Road, Suite 301 Las Vegas, NV
|
|
89118
|
(Address
of principal executive offices)
|
|
(zip
code)
|
Registrant’s
telephone number, including area code: (800) 605-3201
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under
any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
1.01. Entry into a Material Definitive Agreement.
Item
3.02. Unregistered Sales of Equity Securities.
On
February 7, 2021, One World Pharma, Inc. (the “Company”) and ISIAH International, LLC (“ISIAH International”),
entered into a Securities Purchase Agreement (the “Purchase Agreement”) under which ISIAH International agreed to
purchase from the Company, on the dates provided for in the Purchase Agreement, an aggregate of 200,000 shares of the Company’s
newly designated Series B Preferred Stock (“Series B Preferred Stock”), convertible into an aggregate of
20,000,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), for a purchase
price of $15.00 per share of Preferred Stock, and an aggregate purchase price of $3 million. Isiah Thomas, the Company’s
Chief Executive Officer, is the sole member and Chief Executive Officer of ISIAH International.
Concurrently
with the execution of the Purchase Agreement, ISIAH International purchased 16,666 shares of Series B Preferred Stock from the
Company for an aggregate purchase price of $249,990. Pursuant to the Purchase Agreement, ISIAH International has agreed to purchase
shares of Series B Preferred Stock from the Company according to the following schedule:
Date
|
|
Shares
|
|
|
Purchase
Price
|
|
Initial
Closing Date
|
|
|
16,666
|
|
|
$
|
249,990
|
|
February 22,
2021
|
|
|
16,667
|
|
|
$
|
250,005
|
|
March 8, 2021
|
|
|
16,667
|
|
|
$
|
250,005
|
|
March 22,
2021
|
|
|
16,667
|
|
|
$
|
250,005
|
|
April 5, 2021
|
|
|
16,666
|
|
|
$
|
249,990
|
|
April 19,
2021
|
|
|
16,667
|
|
|
$
|
250,005
|
|
May 17, 2021
|
|
|
33,334
|
|
|
$
|
500,010
|
|
June 14, 2021
|
|
|
33,333
|
|
|
$
|
499,995
|
|
July 12, 2021
|
|
|
33,333
|
|
|
$
|
499,995
|
|
Total
|
|
|
200,000
|
|
|
$
|
3,000,000
|
|
The
transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506 of regulation (b)
promulgated thereunder.
Each
share of Series B Preferred Stock has a Stated Value of $15.00 and is convertible into Common Stock at a conversion price equal to $0.15. The conversion price of the Series B Preferred Stock is subject to equitable adjustment in the event of a stock
split, stock dividend or similar event with respect to the Common Stock.
The
information set forth above is qualified in its entirety by reference to the actual terms of the Certificate of Designation of
the Series B Preferred Stock and the Purchase Agreement, which have been filed as Exhibits 3.1 and 10.1, respectively, to this
Current Report on Form 8-K, and which are incorporated herein by reference.
Item
3.03. Material Modification to Rights of Security Holders.
Upon
a liquidation or dissolution of the Company, holders of the Series B Preferred Stock will be entitled to be paid, in preference
to the holders of Common Stock, $15 per share of Series B Preferred Stock.
Item
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On
February 2, 2021, the Company filed the Certificate of Designation of the Series B Preferred Stock of the Company with the Nevada
Secretary of State establishing the terms of the Series B Preferred Stock. The Certificate of Designation has been filed
as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
One
World Pharma, Inc.
|
|
|
|
|
Date:
February 8, 2021
|
|
|
|
|
By:
|
/s/
Bruce Raben
|
|
Name:
|
Bruce
Raben
|
|
Title:
|
Interim
Chief Financial Officer
|
One World Products (QB) (USOTC:OWPC)
Historical Stock Chart
From Mar 2024 to Apr 2024
One World Products (QB) (USOTC:OWPC)
Historical Stock Chart
From Apr 2023 to Apr 2024